Member news

LifeArc partners with Elpida Therapeutics to advance three gene therapies for ultra-rare neurodegenerative diseases in children

Poolbeg announces the positive outcome of a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA)

Firefinch Software sets out what instrument manufacturers need to know about building software that meets Good Manufacturing Practice (GMP) standards

King’s College London has spun out Korecyte Bio Ltd (Korecyte) and Cell and Gene Therapy Catapult (CGT Catapult) has enabled the spinout.

Collaborative Drug Discovery (CDD) announced an agreement with Eli Lilly and Company (Lilly) to integrate Lilly TuneLab, a collaborative AI/ML drug discovery platform, into CDD Vault.

Coulter Partners successfully led a search for Neumirna Therapeutics and is pleased to announce the placement of Dr. Ferenc Tracik as Chief Medical Officer.

Microbiotica announces that all primary and secondary objectives were met in its advanced melanoma (MELODY-1) Phase 1b trial.

Poolbeg will present data on POLB 001 at the European Hematology Association Congress (EHA), taking place 11-14 June 2026 in Stockholm, Sweden.

Cell and Gene Therapy Catapult (CGT Catapult) will provide investment to Lir Therapeutics (Lir) to accelerate the development of nAAVigator, its AI-driven AAV capsid design platform.

Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline.

Brainomix announces an expansion of its partnership with Boehringer Ingelheim to improve the care of patients with progressive pulmonary fibrosis (PPF).

The project will focus on advancing MDX-201, an innovative ADC that links a cytotoxic payload with a first-in-class monoclonal antibody (MDX-124) that targets annexin-A1.

POLB 001 cancer immunotherapy-induced CRS patent granted in Canada, further strengthening Poolbeg's global intellectual property portfolio

Stevenage Bioscience Catalyst is deeply saddened to share the news that our CEO, Dr Sally Ann Forsyth OBE, passed away at home on Saturday 2 May after a long battle with illness.

CellCentric announces oversubscribed $220 Million Series D financing to advance pivotal trials of Inobrodib in Multiple Myeloma

Cytospire Therapeutics announces the closing of an oversubscribed £61 million ($83 million) Series A financing.

Coulter Partners successfully led a search assignment for Laigo Bio and is pleased to announce the placement of Dr. Richard C.A. Sainson as its new Chief Scientific Officer (CSO).

BioOrbit is enabling pharmaceutical drugs to be manufactured in space at scale

Stratosvir has received support from Cell and Gene Therapy Catapult (CGT Catapult), including investment from the Cross Catapult Investment Pilot.

Epitopea announced that it has received approval from MHRA and the REC for its clinical trial application (CTA) for its first-in-human clinical trial (OVACT) of CryptiVax™-1001.